Selected research
Industry Growth & Trends
Global Anti Obesity Drugs Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Anti Obesity Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Anti Obesity Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Anti Obesity Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Anti Obesity Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Anti Obesity Drugs market include Wanhan Pharma, ZENIN Biotechnology, Teva, Novartis, Roche, Lunan Pharma, Eli Lilly, VIVUS and Pharscin Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Anti Obesity Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Anti Obesity Drugs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Anti Obesity Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Anti Obesity Drugs.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Anti Obesity Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Anti Obesity Drugs Market by Company
Wanhan Pharma
ZENIN Biotechnology
Teva
Novartis
Roche
Lunan Pharma
Eli Lilly
VIVUS
Pharscin Pharma
Novo Nordisk
Lupin Laboratories
iNova Pharmaceuticals
Hypera Pharma
GlaxoSmithKline
Alvogen
Anti Obesity Drugs Segment by Type
Injection
Oral
Anti Obesity Drugs Segment by Application
Hospital
Retail Pharmacy
Other
Anti Obesity Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti Obesity Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti Obesity Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti Obesity Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Anti Obesity Drugs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Injection
- Oral
Applications
- Hospital
- Retail Pharmacy
- Other
Companies covered
- Wanhan Pharma
- ZENIN Biotechnology
- Teva
- Novartis
- Roche
- Lunan Pharma
- Eli Lilly
- VIVUS
- Pharscin Pharma
- Novo Nordisk
- Lupin Laboratories
- iNova Pharmaceuticals
- Hypera Pharma
- GlaxoSmithKline
- Alvogen
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Anti Obesity Drugs Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Anti Obesity Drugs Market Size by Region (2021-2032)
- 1.4.1 Global Anti Obesity Drugs Market Size by Region (2021-2026)
- 1.4.2 Global Anti Obesity Drugs Market Size by Region (2027-2032)
- 1.5 Key Regions Anti Obesity Drugs Market Size (2021-2032)
- 1.5.1 North America Anti Obesity Drugs Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Anti Obesity Drugs Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Anti Obesity Drugs Market Size Growth Rate (2021-2032)
- 1.5.4 South America Anti Obesity Drugs Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Anti Obesity Drugs Market Size Growth Rate (2021-2032)
2 Anti Obesity Drugs Market by Type
- 2.1 Type Introduction
- 2.1.1 Injection
- 2.1.2 Oral
- 2.2 Global Anti Obesity Drugs Market Size by Type
- 2.2.1 Global Anti Obesity Drugs Market Size Overview by Type (2021-2032)
- 2.2.2 Global Anti Obesity Drugs Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Anti Obesity Drugs Market Size Forecasted by Type (2027-2032)
- 2.3 Global Anti Obesity Drugs Market Size by Regions
- 2.3.1 North America Anti Obesity Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Anti Obesity Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Anti Obesity Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Anti Obesity Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Anti Obesity Drugs Market Size Breakdown by Type (2021-2026)
3 Anti Obesity Drugs Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital
- 3.1.2 Retail Pharmacy
- 3.1.3 Other
- 3.2 Global Anti Obesity Drugs Market Size by Application
- 3.2.1 Global Anti Obesity Drugs Market Size Overview by Application (2021-2032)
- 3.2.2 Global Anti Obesity Drugs Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Anti Obesity Drugs Market Size Forecasted by Application (2027-2032)
- 3.3 Global Anti Obesity Drugs Market Size by Regions
- 3.3.1 North America Anti Obesity Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Anti Obesity Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Anti Obesity Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Anti Obesity Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Anti Obesity Drugs Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Anti Obesity Drugs Industry Trends
- 4.2 Anti Obesity Drugs Industry Drivers
- 4.3 Anti Obesity Drugs Industry Opportunities and Challenges
- 4.4 Anti Obesity Drugs Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Anti Obesity Drugs Revenue (2021-2026)
- 5.2 Global Anti Obesity Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Anti Obesity Drugs Key Company Headquarters & Area Served
- 5.4 Global Anti Obesity Drugs Company, Product Type & Application
- 5.5 Global Anti Obesity Drugs Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Anti Obesity Drugs Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Anti Obesity Drugs Players Market Share by Revenue in 2025
- 5.6.3 2025 Anti Obesity Drugs Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Wanhan Pharma
- 6.1.1 Wanhan Pharma Company Information
- 6.1.2 Wanhan Pharma Business Overview
- 6.1.3 Wanhan Pharma Anti Obesity Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Wanhan Pharma Anti Obesity Drugs Product Portfolio
- 6.1.5 Wanhan Pharma Recent Developments
- 6.2 ZENIN Biotechnology
- 6.2.1 ZENIN Biotechnology Company Information
- 6.2.2 ZENIN Biotechnology Business Overview
- 6.2.3 ZENIN Biotechnology Anti Obesity Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 ZENIN Biotechnology Anti Obesity Drugs Product Portfolio
- 6.2.5 ZENIN Biotechnology Recent Developments
- 6.3 Teva
- 6.3.1 Teva Company Information
- 6.3.2 Teva Business Overview
- 6.3.3 Teva Anti Obesity Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Teva Anti Obesity Drugs Product Portfolio
- 6.3.5 Teva Recent Developments
- 6.4 Novartis
- 6.4.1 Novartis Company Information
- 6.4.2 Novartis Business Overview
- 6.4.3 Novartis Anti Obesity Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Novartis Anti Obesity Drugs Product Portfolio
- 6.4.5 Novartis Recent Developments
- 6.5 Roche
- 6.5.1 Roche Company Information
- 6.5.2 Roche Business Overview
- 6.5.3 Roche Anti Obesity Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Roche Anti Obesity Drugs Product Portfolio
- 6.5.5 Roche Recent Developments
- 6.6 Lunan Pharma
- 6.6.1 Lunan Pharma Company Information
- 6.6.2 Lunan Pharma Business Overview
- 6.6.3 Lunan Pharma Anti Obesity Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Lunan Pharma Anti Obesity Drugs Product Portfolio
- 6.6.5 Lunan Pharma Recent Developments
- 6.7 Eli Lilly
- 6.7.1 Eli Lilly Company Information
- 6.7.2 Eli Lilly Business Overview
- 6.7.3 Eli Lilly Anti Obesity Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Eli Lilly Anti Obesity Drugs Product Portfolio
- 6.7.5 Eli Lilly Recent Developments
- 6.8 VIVUS
- 6.8.1 VIVUS Company Information
- 6.8.2 VIVUS Business Overview
- 6.8.3 VIVUS Anti Obesity Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 VIVUS Anti Obesity Drugs Product Portfolio
- 6.8.5 VIVUS Recent Developments
- 6.9 Pharscin Pharma
- 6.9.1 Pharscin Pharma Company Information
- 6.9.2 Pharscin Pharma Business Overview
- 6.9.3 Pharscin Pharma Anti Obesity Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Pharscin Pharma Anti Obesity Drugs Product Portfolio
- 6.9.5 Pharscin Pharma Recent Developments
- 6.10 Novo Nordisk
- 6.10.1 Novo Nordisk Company Information
- 6.10.2 Novo Nordisk Business Overview
- 6.10.3 Novo Nordisk Anti Obesity Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Novo Nordisk Anti Obesity Drugs Product Portfolio
- 6.10.5 Novo Nordisk Recent Developments
- 6.11 Lupin Laboratories
- 6.11.1 Lupin Laboratories Company Information
- 6.11.2 Lupin Laboratories Business Overview
- 6.11.3 Lupin Laboratories Anti Obesity Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Lupin Laboratories Anti Obesity Drugs Product Portfolio
- 6.11.5 Lupin Laboratories Recent Developments
- 6.12 iNova Pharmaceuticals
- 6.12.1 iNova Pharmaceuticals Company Information
- 6.12.2 iNova Pharmaceuticals Business Overview
- 6.12.3 iNova Pharmaceuticals Anti Obesity Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 iNova Pharmaceuticals Anti Obesity Drugs Product Portfolio
- 6.12.5 iNova Pharmaceuticals Recent Developments
- 6.13 Hypera Pharma
- 6.13.1 Hypera Pharma Company Information
- 6.13.2 Hypera Pharma Business Overview
- 6.13.3 Hypera Pharma Anti Obesity Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Hypera Pharma Anti Obesity Drugs Product Portfolio
- 6.13.5 Hypera Pharma Recent Developments
- 6.14 GlaxoSmithKline
- 6.14.1 GlaxoSmithKline Company Information
- 6.14.2 GlaxoSmithKline Business Overview
- 6.14.3 GlaxoSmithKline Anti Obesity Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 GlaxoSmithKline Anti Obesity Drugs Product Portfolio
- 6.14.5 GlaxoSmithKline Recent Developments
- 6.15 Alvogen
- 6.15.1 Alvogen Company Information
- 6.15.2 Alvogen Business Overview
- 6.15.3 Alvogen Anti Obesity Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.15.4 Alvogen Anti Obesity Drugs Product Portfolio
- 6.15.5 Alvogen Recent Developments
7 North America
- 7.1 North America Anti Obesity Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Anti Obesity Drugs Market Size by Country (2021-2026)
- 7.3 North America Anti Obesity Drugs Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Anti Obesity Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Anti Obesity Drugs Market Size by Country (2021-2026)
- 8.3 Europe Anti Obesity Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Anti Obesity Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Anti Obesity Drugs Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Anti Obesity Drugs Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Anti Obesity Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Anti Obesity Drugs Market Size by Country (2021-2026)
- 10.3 South America Anti Obesity Drugs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Anti Obesity Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Anti Obesity Drugs Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Anti Obesity Drugs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst